INTEGRIN TARGETING LIGANDS AND USES THEREOF
Synthetic αvβ6 integrin ligands of Formula I having serum stability and affinity for integrin αvβ6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin αvβ6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include αvβ6 integrin ligands and methods of use are also described.
1 . A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
R 1 is optionally substituted alkyl, optionally substituted alkoxy, or
wherein R 11 and R 12 are each independently optionally substituted alkyl or a cargo molecule, or R 1 is a cargo molecule;
R 2 is H, optionally substituted alkyl, or a cargo molecule;
R 3 is H or optionally substituted alkyl;
R 4 is H or optionally substituted alkyl;
R 5 is H or optionally substituted alkyl;
R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, optionally substituted amino, or a cargo molecule;
Q is optionally substituted aryl or optionally substituted alkylene;
X is O, CR 8 R 9 , NR 8 ;
wherein R 8 is selected from H, optionally substituted alkyl, or R 8 is taken together with Rx or Ry to form a 4-, 5-, 6-, 7-, 8- or 9-membered ring, and R 9 is H or optionally substituted alkyl;
Rx and Ry are each independently H, optionally substituted alkyl, a cargo molecule or Rx and Ry may be taken together to form a double bond with R 10 , wherein R 10 is H, optionally substituted alkyl, or R 10 may be taken together with X and the atoms to which it is attached to form a 4-, 5-, 6-, 7-, 8, or 9-membered ring;
wherein at least one of R 1 , R 2 , R 6 , R 11 , R 12 , Rx and Ry comprise a cargo molecule; and
wherein when Q is optionally substituted alkyl and the length of the optionally substituted alkyl chain represented by Q is 3 carbons, then R 1 is
2 . The compound of claim 1 , wherein the compound is a compound of Formula Ia:
wherein R 18 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, —NR 19 R 20 , wherein R 19 and R 20 are each independently H or optionally substituted alkyl.
3 . The compound of claim 1 , wherein the compound is a compound of Formula Ib:
4 . The compound of claim 1 , wherein the compound is a compound of Formula Ic:
5 . The compound of claim 1 , wherein the compound is a compound of Formula Id:
wherein R 18 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, —NR 19 R 20 , wherein R 19 and R 20 are each independently H or optionally substituted alkyl.
6 - 7 . (canceled)
8 . The compound of claim 1 , wherein Q is
wherein R 15 and R 16 are each independently H,
wherein R 17 is optionally substituted alkyl, or optionally substituted alkyl; and n is an integer from 1 to 10.
9 - 15 . (canceled)
16 . The compound of claim 1 , wherein R 1 comprises at least one polyethylene glycol (PEG) unit.
17 - 21 . (canceled)
22 . The compound of claim 1 , wherein the compound has the formula.
Compound
Number
Formula
41a
42a
43a
44a
45a
46a
47a
48a
49a
50a
51a
52a
53a
54a
55a
56a
57a
58a
59a
or
60a
or a pharmaceutically acceptable salt thereof, and wherein indicates the point of connection to a cargo molecule.
23 . The compound of claim 1 , wherein the compound has the formula:
Compound
Number
Formula
41b
42b
43b
44b
45b
46b
47b
48b
49b
50b
51b
52b
53b
54b
55b
56b
57b
58b
59b
60b
or a pharmaceutically acceptable salt thereof, and wherein indicates the point of connection to a cargo molecule.
24 . The compound of claim 1 , wherein the cargo molecule comprises an RNAi agent.
25 . (canceled)
26 . The compound of claim 24 , wherein the compound is bound to the 5′ end of the sense strand of the RNAi agent.
27 . A compound of Formula Ip:
or a pharmaceutically acceptable salt thereof, wherein
R 1 is optionally substituted alkyl, optionally substituted alkoxy, or
wherein R 11 and R 12 are each independently optionally substituted alkyl or a linking moiety, or R 1 is a linking moiety;
R 2 is H, optionally substituted alkyl, or a moiety;
R 3 is H or optionally substituted alkyl;
R 4 is H or optionally substituted alkyl;
R 5 is H or optionally substituted alkyl;
R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, optionally substituted amino, or a linking moiety;
Q is optionally substituted aryl or optionally substituted alkylene;
X is O, CR 8 R 9 , NR 8 ;
wherein R 8 is selected from H, optionally substituted alkyl, or R 8 is taken together with Rx or Ry to form a 4-, 5-, 6-, 7-, 8- or 9-membered ring, and R 9 is H or optionally substituted alkyl;
Rx and Ry are each independently H, optionally substituted alkyl, a cargo molecule or Rx and Ry may be taken together to form a double bond with R 10 , wherein R 10 is H, optionally substituted alkyl, or R 10 may be taken together with X and the atoms to which it is attached to form a 4-, 5-, 6-, 7-, 8, or 9-membered ring;
wherein at least one of R 1 , R 2 , R 6 , R 11 , R 12 , Rx and Ry comprise a linking moiety; and
wherein when Q is optionally substituted alkyl and the length of the optionally substituted alkyl chain represented by Q is 3 carbons, then R 1 is
28 . The compound of claim 27 , wherein the linking moiety comprises a functional group selected from the group consisting of: azide, ester, carbamate, alkene, alcohol, amine, amide, carbonate, and alkyne.
29 . (canceled)
30 . The compound of claim 27 , wherein the compound has the formula:
Compound
Number
Formula
41p
42p
43p
44p
45p
46p
47p
48p
49p
50p
51p
52p
53p
54p
55p
56p
57p
58p
59p
60p
or an acceptable salt thereof.
31 . A method of making a compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein
R 1 is optionally substituted alkyl, optionally substituted alkoxy, or
wherein R 11 and R 12 are each independently optionally substituted alkyl or a cargo molecule, or R 1 is a cargo molecule;
R 2 is H, optionally substituted alkyl, or a cargo molecule;
R 3 is H or optionally substituted alkyl;
R 4 is H or optionally substituted alkyl;
R 5 is H or optionally substituted alkyl;
R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, optionally substituted amino, or a cargo molecule;
Q is optionally substituted aryl or optionally substituted alkylene;
X is O, CR 8 R 9 , NR 8 ;
wherein R 8 is selected from H, optionally substituted alkyl, or R 8 is taken together with Rx or Ry to form a 4-, 5-, 6-, 7-, 8- or 9-membered ring, and R 9 is H or optionally substituted alkyl;
Rx and Ry are each independently H, optionally substituted alkyl, a cargo molecule or Rx and Ry may be taken together to form a double bond with R 10 , wherein R 10 is H, optionally substituted alkyl, or R 10 may be taken together with X and the atoms to which it is attached to form a 4-, 5-, 6-, 7-, 8, or 9-membered ring;
wherein at least one of R 1 , R 2 , R 6 , R 11 , R 12 , Rx and Ry comprise a cargo molecule; and
wherein when Q is optionally substituted alkyl and the length of the optionally substituted alkyl chain represented by Q is 3 carbons, then R 1 is
comprising reacting a compound of Formula Ip
or a pharmaceutically acceptable salt thereof, wherein
R 1 is optionally substituted alkyl, optionally substituted alkoxy, or
wherein R 11 and R 12 are each independently optionally substituted alkyl or a linking moiety, or R 1 is a linking moiety;
R 2 is H, optionally substituted alkyl, or a linking moiety;
R 3 is H or optionally substituted alkyl;
R 4 is H or optionally substituted alkyl;
R 5 is H or optionally substituted alkyl;
R 6 is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkoxy, halo, optionally substituted amino, or a linking moiety;
Q is optionally substituted aryl or optionally substituted alkylene;
X is O, CR 8 R 9 , NR 8 ;
wherein R 8 is selected from H, optionally substituted alkyl, or R 8 is taken together with Rx or Ry to form a 4-, 5-, 6-, 7-, 8- or 9-membered ring, and R 9 is H or optionally substituted alkyl;
Rx and Ry are each independently H, optionally substituted alkyl, a cargo molecule or Rx and Ry may be taken together to form a double bond with R 10 , wherein R 10 is H, optionally substituted alkyl, or R 10 may be taken together with X and the atoms to which it is attached to form a 4-, 5-, 6-, 7-, 8, or 9-membered ring;
wherein at least one of R 1 , R 2 , R 6 , R 11 , R 12 , Rx and Ry comprise a linking moiety; and
wherein when Q is optionally substituted alkyl and the length of the optionally substituted alkyl chain represented by Q is 3 carbons, then R 1 is
with a cargo molecule comprising a reactive moiety.
32 . The method of claim 31 , wherein the cargo molecule is an RNAi agent.
33 . The method of claim 32 , wherein the linking moiety comprises an azide and the reactive moiety is an alkyne.
34 . A composition comprising the compound of claim 1 , and a pharmaceutically acceptable excipient.
35 . The composition of claim 34 , wherein the cargo molecule is an RNAi agent targeting a gene located in a skeletal muscle cell.
36 . (canceled)
37 . A method of treating or preventing a disease or disorder that may be treated or ameliorated by knocking down gene expression in skeletal muscle cells comprising administering to a subject in need thereof a pharmaceutical composition comprising the composition of claim 34 .
38 . (canceled)